Stay updated on Eplontersen in ATTR CM: Clinical Trial
Sign up to get notified when there's something new on the Eplontersen in ATTR CM: Clinical Trial page.

Latest updates to the Eplontersen in ATTR CM: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to include new information about Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) and the EudraCT number for ION-682884-CS2, while significant details regarding the study's design and inclusion/exclusion criteria have been removed.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and removed a date reference of March 25, 2025, while adding a new date of December 27, 2024.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous version (v2.14.2) and last update date of December 27, 2024.SummaryDifference0.3%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Eplontersen in ATTR CM: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eplontersen in ATTR CM: Clinical Trial page.